Treatment of chronic hepatite B;Traitement de l'hépatite chronique B

Gastroenterologie Clinique et Biologique

Volumn 28, Issue 12, 2004, Pages 1215-1227

  Asselah, Tarik ^a   Castelnau, Corinne ^a   Boyer, Nathalie ^a   Ripault, Marie Pierre ^a   Marcellin, Patrick ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; CLEVUDINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B VACCINE; IMMUNOMODULATING AGENT; INTERFERON; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT HEPATITIS B VACCINE; TELBIVUDINE; TENOFOVIR;

CHRONIC HEPATITIS; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER BIOPSY; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 11244354416     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(04)95213-X     Document Type: Short Survey

References (69)

1. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003;39(suppl 1):S3-25.
2. Lok AS, McMahon BJ. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Chronic hepatitis B. Hepatology 2001;34:1225-41.
3. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004;350:1118-29.
4. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000;32:477-81.
5. Nousbaum JB, Cadranel JF, Bonnemaison G, Bourliere M, Chiche L, Chor H, et al. Recommandations pour la pratique clinique pour la réalisation de la ponction biopsie hépatique. Gastroenterol Clin Biol 2002;26:848-78.
6. Myers RP, Tainturier MH, Ratziu V. Piton A, Thibault V. Imbert-Bismuth F, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003;39:222-30.
7. Wai CT, Chu CJ, Hussain M. Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002;36:1425-30.
8. Janssen HLA, Sentruk H, Zeuzem S, Schalm SW, et al. Peginterferon alfa 2b and lamivudine combination therapy compared with peginterferon alfa 2b for chronic HbeAg-positive hepatitis B: a randomized controlled trial in 307 patients. Hepatology 2003;38:246A.
9. th, Yang H, Chen SS, Marcellin P, Hadziyannis S. et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase 111 studies of adefovir dipivoxill. Gastroenterology 2003;125:107-16.
10. Thomas H, Foster G, Platis D. Mechanisms of action of interferon and nucleoside analogues. J Hepatol 2003;39(Suppl 1):S93-8.
11. Asselah T, Boyer N. Marcellin P. Traitement de l'hépatite C. Encycl Med Chir. Hépatologie 2003;7-015-B-51.
12. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-23.
13. Craxi A, Di Bona D, Camma C. Interferon-alpha for HBeAg-positive chronic hepatitis B. J Hepatol 2003:39(suppl):S99-105.
14. Brunette MR, Oliveri F, Colombatto P, Coco B, Ciccorossi P, Bonino F. Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon. J Hepatol 2003;39(suppl 1):S164-7.
15. Gervais A, Boyer N, Marcellin P. Tolerability of treatments for viral hepatitis. Drug Saf 2001;24:375-84.
16. Marcellin P, Pouteau M, Benhamou JP. Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. J Hepatol 1995:22:364-9.
17. Boyer N, Marcellin P. L'interféron pégylé: nouveau progrès dans le traitement de l'hépatite chronique virale C. Gastroenterol Clin Biol 2000;24:767-9.
18. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305.
19. Marcellin P, Lau GKK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg - negative chronic hepatitis B. N Engl J Med 2004;351:1206-17.
20. Koskinas J, Merkouraki P, Manesis E, Hadziyannis S. Assessment of depression in patients with chronic hepatitis: effect of interferon treatment. Dig Dis 2002;20:284-8.
21. Lai CL, Chien RN, Leung NW. Chang TT, Guan R, Tai DI, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-8.
22. Dienstag JL, Schiff E, Wright T, Perrillo R, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
23. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-10.
24. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. On behalf of the Asia Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32.
25. Jonas MM, Kelley DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, et al. International Pediatric Lamivudine Investigator Group. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-13.
26. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-17.
27. Liaw YF. Results of lamivudine trials in Asia. J Hepatol 2003;39(Suppl 1):S111-5.
28. Song BC, Suh DJ, Lee H C, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-6.
29. Zoulim F. Hepatitis B virus resistance to antivirals: clinical implications and management. J Hepatol 2003;39(Suppl 1):S133-8.
30. Honkoop P, de Man RA, Niesters HGM, Zondervan PE, Schalm SW. Severe acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635-9.
31. Tassopoulos N, Hadziyannis S, Cianciara J, Rizzetto M, Schiff E, Pastore G, et al. Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy. Hepatology 2001;34:341A.
32. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002;36:219-26.
33. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16.
34. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7.
35. Hadziyannis S, Tassopoulos N, Chang TT, Heathcote J, Kitis G, Rizzetto M, et al. Three year study of adefovir dipivoxil demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B patients in a long term safety and efficacy study. J Hepatol 2004;40(Suppl 1):46A.
36. Perrillo RP, Schiff ER, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir Dipivoxil for the treatment of lamivudine-resistanl hepatitis B mutants. Hepatology 2000;32:129-34.
37. Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. On behalf of the Adefovir Dipovoxil Study 435 International Investigators Group. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003;38:1419-27.
38. Peters MG, Hann HW. Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamtvudtne-resistant chronic hepatitis B. Gastroenterology 2004;126:91-101.
39. Perrillo R, Hann HW, Muttmer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:81-90.
40. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH. Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resislant hepatitis B virus: an open-label pilot study. Lancet 2001;358:718-23.
41. Serfaty L, Thabut D, Zoulim F, Andreani T, Chazouilleres O, Carbonell N, et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology 2001;34:573-7.
42. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. nternational Lamivudine Study Group. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-8.
43. Barbara G, Zechini F, Pellicelli AM, Francavilla R, Scotto G, Bacca D, et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol 2001;35:406-11.
44. Schiff ER, Dienstag JL, Karayalcin S, Grimm IS, Perillo RP, Husa P, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003;38:818-26.
45. Santantonio T, Niro GA, Sinisi E, Leandro G, Insalata M, Guastadisegni A, et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol 2002;36:799-804.
46. Tatulli I, Francavilla R, Rizzo GL, Vinciguerra V, lerardi E, Amoruso A, et al. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. J Hepatol 2001;35:805-10.
47. Sung JJY, Lai JY, Zeuzem S, Chow WC, Heathcote E, Perrillo R, et al. A randomised double blind phase II study of lamivudine compared to lamivudine plus adefovir dipivoxil for treatment naive patient with chronic hepatitis B; week 52 analysis (résumé). J Hepatol 2003;38:69A.
48. De Man RA, Wolters LMM, Nevens F, Chua D, Sherman M, Lai CL, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001;34:578-82.
49. Gish R, Chang TT, Hadziyannis S, Cianciara J, Rizetto M, Schiff E, et al. Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in HBeAg negative and positive patients with chronic hepatitis B who have failed prior lamivudine therapy (résumé). J Hepatol 2003;38:93A.
50. Shakil AO, Lilly L, Angus P, Gerken G,Thomas N. Entecavir reduces viral load in liver transplant patients who have failed prophylaxis or treatment for hepatitis B (résumé). Hepatology 2001;34:619A.
51. Yao GB, Wang B, Zhou X, Zhang D, Xu D, Liu J, et al. A phase II study in China of the safety & antiviral activity of entecavir in adults with chronic hepatitis B infection (résumé). Hepatology 2003;38:1152A.
52. Leung N, Gish RG, Wang C, Sacks S, Fried M, Wright T, et al. A randomized, double-blind, comparison of 3 doses of emtricitabine (FTC) in patients whith chronic hepatitis B (CHB) given 48 weeks of treatment (FTCB-102) (résumé). Hepatology 2001;34:349A.
53. Gish R, Wright T, Wang C, and others. Emtricitabine (Coviracil: FTC): Results from a 24 week dose-selection trial in patients with chronic HBV infection (résumé). Hepatology 2000:873A.
54. Marcellin P, Mommeja-Marin H, Sacks SL. Lau GK, Sereni D, Bronowicki JP et al. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 2004;40:140-8.
55. Van Bömmel F, Wünsche T, Schürmann D, Bergk A, Wiedenmann B, Hopf U, et al. A comparison of adefovir and tenofovir in the treatment of lamivudine resistant hepatitis B virus infection (résumé). Hepatology 2003;38:246A.
56. Han SH, Leung NWY, Teo EK, Tong M, Wong F, Hann HW, et al. Results of a one year international phase 11B trial of LDT, and LDT plus lamivudine, in patients with chronic hepatitis B (résumé). J Hepatol 2004;40(Suppl 1):42A.
57. Lebray P, Vallet-Pichard A, Michel ML, Fontaine H, Sobesky R, Brechet C, et al. Immunomodulatory drugs and therapeutic vaccine in chronic hepatitis B infection. J Hepatol 2003;39(Suppl 1):S151-9.
58. Marcellin P, Loriot MA, Boyer N, Martinot-Peignoux M, Degott C, Degos F, et al. Recombinant human gamma-interferon in patients with chronic active hepatitis B: pharmacokinetics, tolerance and biological effects. Hepatology 1990;12:155-8.
59. Habersetzer F, Boyer N, Marcellin P, Bailly F, Ahmed SN, Alam J, et al. A pilot study of recombinant Interferon beta-1 a for the treatment of chronic hepatitis C. Liver 2000;20:437-41.
60. Thibault V, Delaugerre C, Calvez V, Costagliola D, Tubiana R, Katlama C. Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus-infected patients: results from a randomized control trial. Hepatology 2002;35:238-9.
61. Carreno V, Zeuzem S, Hopf U, Marcellin P, Cooksley WG, Fevery J, et al. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. J Hepatol 2000;32:317-24.
62. Chan HL, Tang JL, Tarn W, Sung JJ. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysts. Aliment Pharmacol Ther 2001;15:1899-905.
63. Pol S, Nalpas B, Driss F, Michel ML, Tiollais P, Denis J, et al. Multicenter study group. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 2001;34:917-21.
64. Akbar SMZ, Joko K, Yamamoto K, Shimin M, Kojima N, Abe M, et al. Increased therapeutic potential and fewer effects in patients with chronic hepatitis B receiving a combination of lamivudine and vaccine therapy; role of antigen presenting dendritic cells (résumé). Hepatology 2003;38:244A.
65. Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002;36:263-70.
66. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001;34:306-13.
67. Lampertico P, Del Ninno E, Vigano M, Romeo R, Donato MF, Sablon E, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month Interferon therapy. Hepatology 2003;37:756-63.
68. Liaw YF, Sung JJY, Chow WC, Shue K, Keene O, Farrell G. Effects of lamivudineon disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blind placebo controlled clinical trial. Hepatology 2003;38:220A.
69. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. The Taiwan Childhood Hepatoma Study Group Universal Hepatitis B Vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997;336:1855-9.